Protalix BioTherapeutics, Inc. — Director's Dealing 2012

Jul 18, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protalix BioTherapeutics, Inc. (PLX)
CIK: 0001006281
Period of Report: 2012-07-16

Reporting Person: Almon Einat Brill (SVP, Product Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-07-16	Common Stock	A	185000	—	Acquired	185000	Indirect

Footnotes

F1: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., issued under its 2006 Stock Incentive Plan, as amended June 17, 2012 (the "Plan"). The restricted shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. In addition to the vesting period, vested restricted shares will be subject to a lock-up for a 24-month period. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan, and the lock-up period will terminate.

F2: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.